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cD4 T-cell Dysregulation in Psoriatic 
arthritis reveals a regulatory role 
for il-22
Amara Ezeonyeji1, Helen Baldwin1, Milica Vukmanovic-Stejic2 and Michael R. Ehrenstein1*
1 Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 2 Division of Infection 
and Immunity, University College London, London, United Kingdom
Dysregulation of interleukin-22 (IL-22) has been associated with autoimmune dis-
eases but divergent effects upon inflammation have hampered efforts to define its 
contribution to pathogenesis. Here, we examined the role of IL-22 in patients with 
psoriatic arthritis (PsA). In the peripheral blood of PsA patients, there was a decrease 
in IL-22+CD4+ T cells compared with healthy controls resulting in a heightened CD4+ 
IFNγ+/IL-22+ ratio accompanied by diminished CCR6 expression. IL-22 expressing cells 
were depleted primarily from the central memory CD4 T-cell subset in PsA patients. 
Paradoxically IL-22 and particularly interferon-gamma (IFNγ) production were elevated 
within a CD4+ T-cell subset with phenotypic markers characteristic of naïve T  cells 
(CD3+CD4+CD27+CD45RA+CCR7+CD95−IL-2Rβ−) from PsA patients with the highest 
IFNγ+/IL-22+ ratio of all the CD4 subsets. These unconventional “naïve” CD4+ T cells 
from PsA patients displayed some phenotypic and functional characteristics of memory 
cells including a marked proliferative response. Increased IFNγ production from these 
unconventional “naïve” T cells from PsA patients promoted greater expression of the 
chemo-attractant CXCL9 by HaCaT keratinocytes compared with their healthy counter-
parts. Treatment with anti-TNF therapy reversed these abnormalities in this T-cell subset 
though did not affect the frequency of IL-22+ T cells overall. Furthermore, blockade of 
IL-22 enhanced the IFNγ mediated release of CXCL-9. These results reveal CD4+ T-cell 
dysregulation in patients with PsA which can be reversed by anti-TNF and highlight the 
regulatory properties of IL-22 with important implications for therapeutic approaches 
that inhibit its production.
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inTrODUcTiOn
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis (1). TNF-α and IL-17 
axis have been implicated in the pathogenesis of psoriasis and PsA (2, 3), although there is a 
stronger IL-17 signature in the skin compared with the synovium (4). Serum levels of a variety of 
cytokines including TNF, IL-17, and IL-22 have been positively correlated with psoriasis and PsA 
though the results have not always been consistent (5–9).
Interleukin-22 (IL-22) is member of the interleukin-10 (IL-10) family produced by lymphocytes 
but unlike other cytokines exerts its effects predominantly upon non-hemopoietin cells. IL-22 
acts upon epithelial cells and fibroblasts at barrier sites such as the skin, lungs, gut, and synovium 
Table 1 | Clinical features of the patients studied.
samples healthy Psa patients
Sample number total 41 83
sex
Male 8 39
Female 33 44
age
35.4 49.3 ± 2.1
Pattern of arthritis
Peripheral arthritis 65
Oligoarthritis 5
Axial involvement 9
Enthesitis 4
Active psoriasis (% patients) 67%
Treatment type
Untreated 33
DMARD 30
Adalimumab 20
Untreated patients
TJC 7.2 ± 1.76
SJC 4.5 ± 0.35
PASI 1.9 ± 0.63
ESR 15.4 ± 2.39
CRP 6.1 ± 1.45
DAS 28 ESR 3.3 ± 0.26
DMarD patients
TJC 6.7 ± 2.64
SJC 2.1 ± 0.84
PASI 1.3 ± 0.35
ESR 16.5 ± 4.12
CRP 8.0 ± 1.42
DAS 28 ESR 2.8 ± 0.31
adalimumab patients
TJC 2.2 ± 0.62
SJC 1.9 ± 0.66
PASI 3.7 ± 1.97
ESR 8.4 ± 1.88
CRP 5.3 ± 2.78
DAS 28 ESR 2.3 ± 0.29
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where it has been shown to be antiapoptotic, antimicrobial, 
pro-proliferative, and to promote cell survival and tissue regen-
eration (10). Dysregulation of IL-22 is thought to contribute to 
the development of a number of autoimmune diseases includ-
ing psoriasis but also Crohn’s disease, and rheumatoid arthritis 
(11–13). IL-22 from dermal CD4+ T cells is highly expressed in 
lesional skin of psoriasis patients, and peripheral blood levels 
of IL-22 correlate strongly with disease activity, although these 
blood levels do not predict response to therapy (12). Relevant 
to psoriasis, IL-22 promotes keratinocyte proliferation, disrupts 
normal keratinocyte differentiation, and acts in concert with 
IL-17 to release pro-inflammatory cytokines and chemokines 
(2). Less is known about its role in inflamed joints of PsA.
While the role of IL-22 in psoriasis is generally considered to 
be uniformly pro-inflammatory, IL-22 also possesses regulatory 
and tissue protective properties in other settings (14). IL-22-
deficient mice have increased susceptibility to hepatitis and 
similarly overexpression of the IL-22 gene in a mouse model of 
ulcerative colitis rescues the disease phenotype (15, 16). These 
protective effects are considered to be mediated through its action 
on target tissues rather than on dampening immune responses. 
To complicate matters further, IL-22 has both protective and 
pro-inflammatory effects in a number of diseases including 
asthma and collagen-induced arthritis depending upon the 
timing of administration (17–19). In a recent landmark paper, 
IL-22 was shown to have regulatory properties in inflammatory 
bowel disease (20).
In this study, we show that IL-22 is dysregulated in patients 
with PsA, particularly in the naïve CD4 T-cell compartment, 
and that IL-22 may operate as a regulatory cytokine to control 
inflammation.
MaTerials anD MeThODs
Patients and controls
We recruited patients with a diagnosis of PsA and healthy vol-
unteers. Patients were either untreated, receiving a conventional 
disease modifying agent, or treated with anti-TNF therapy 
(adalimumab). See Table 1 for a summary of the clinical informa-
tion. The study was approved by the UK NHS Health Research 
Authority, London City Road and Hampstead Committee, and 
written informed consent was obtained from all participants.
antibodies and Flow cytometry
The following antibodies were used: Alexa Fluor 700-conjugated 
CD4 (clone RPA-TA; BD) or V500-conjugated CD4 (clone 
RPA-T4; BD); Alexa Fluor 700-conjugated-CD3 (clone OKT3; 
Biolegend); Alexa Fluor 488-conjugated CD3 (clone SP34-2; 
BD); Brilliant violet 711-conjugated CD8a (clone RPA-TA; BD); 
Alexa Fluor 488-conjugated IL-17A (clone BL168; Biolegend); 
PE Cy7 PE-Cyanine7-conjugated IL-22 (clone 22URTI eBiosci-
ence); V450-conjugated IFN-γ (clone B27, eBioscience); Brilliant 
Violet 605-conjugated CCR6 (Lone G034E3; Biolegend); PerCP/
Cy5.5-conjugated CD194 (CCR4) (clone L291H4; Biolegend); 
PE-CF594-conjugated CD183 (CXCR3) (clone 1C6; BD); 
PE-conjugated CCR10 (clone 6588-5; eBioscience); PerCP-eFluor 
710-conjugated Ki67 (clone 20Raj; eBioscience); APC-conjugated 
CD27 (clone O323; eBioscience); APC-H7-conjugated CD27 
(clone M-T27; BD); PE-conjugated CD45RA (clone HI 100; BD); 
Alexa Fluor 700-conjugated CD45RA (clone Hi100, Biolegend); 
PE-Cy7-conjugated CD197 (CCR7) (clone 3D12; BD); 
FITC-conjugated CD62L (clone DREG-56; BD); PE-conjugated 
CXCL-9 (clone 49106; R&D systems); PE-conjugated mouse 
IgG1 isotype (clone 11711; R&D systems); Pacific blue™-
con jugated mouse anti-STAT1 (pY701) (clone 14/P-STAT1); 
Pacific blue™-conjugated mouse IgG1κ isotype control (clone 
MOPC-21; BD); antihuman/mouse IL-22 functional grade puri-
fied (clone IL-22JOP; eBioscience); Rat IgG2aκ isotype control 
functional grade purified (clone eBR2a, eBioscience); antihuman 
IFNγ functional grade purified (NIB42 eBioscience); mouse 
IgG1κ isotype control functional grade purified (clone p3.6.2.8.1; 
eBioscience); soluble anti-CD3 (HIT-3a; eBioscience); and solu-
ble anti-CD28 (CD28.2; eBioscience). All samples were acquired 
on an LSR II flow cytometer (BD) unless otherwise stated. Data 
were analyzed using FlowJo v10 software (TreeStar, Ashland, 
OR, USA).
3Ezeonyeji et al. IL-22 in Psoriatic Arthritis
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1403
PbMc isolation surface staining  
and cell culture
Whole peripheral blood mononuclear cells (PBMCs) were iso-
lated by Ficoll-Paque (GE Healthcare) density gradient centrifu-
gation using standard methods. Surface staining experiments 
were performed in accordance with manufacturer’s instruc-
tions. The eBioscience fixation/permeabilization buffer set was 
used for all intracellular staining experiments. The secretion of 
IL-22, IFNγ, and IL-17 was determined by flow cytometry after 
stimulation with soluble anti-CD3 (1  µg/mL) and anti-CD28 
(1 µg/mL) for 3–5 days followed by 4-h stimulation with phor-
bol myristate acetate (PMA) (40  ng/mL) (Sigma), ionomycin 
(250 ng/mL) (Sigma), and Golgi-Stop™ 1 µg/mL (BD). LIVE/
DEAD™ Fixable Blue Dead Cell Stain Kit was used to exclude 
dead cells.
Facs and culture of cD4+ T-cell subsets
Naïve (CD3+ CD4+ CD45RA+CD27+), central memory (CD3+ 
CD4+ CD45RA− CD27+), and effector memory (CD3+ CD4+ 
CD45RA− CD27−) T-cell subsets were isolated from whole PBMCs 
by flow cytometry (BD FACS Aria). Cell purity was evaluated 
after cell sorting by flow cytometry. Cells were then stimulated 
with soluble anti-CD3/anti-CD28 with or without recombinant 
IL-21 (30 ng/mL) (Peprotech) and cultured for 3–5 days. T-cell 
supernatants were taken for ELISA at culture day 3 in cells 
cul tured without accessory cells. IL-22 and IFNγ secretion was 
measured at day 5 by flow cytometry as described.
Ki67 expression
Purified naïve (CD3+ CD4+ CD45RA+CD27+) T  cells were 
stained for Ki67 expression at day 0 and following 5-day stimula-
tion with soluble anti-CD3/anti-CD28 (1 µg/mL) and restimula-
tion with PMA, ionomycin, and Golgi stop as outlined above.
cytokine Measurements by elisa
ELISA kits measuring IL-22 (R&D systems) and IFNγ (eBiosci-
ence) were used to assay cytokines in culture supernatants in 
accordance with the manufacturer’s instructions.
hacaT cell culture and chemokine 
Detection
HaCaT  cells (a keratinocyte cell line) were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma) sup-
plemented with 5% fetal bovine serum and 0.5% penicillin/
streptomycin. HaCaT  cells were stimulated with either 
recombinant IFNγ (1 ng/mL) (Peprotech) and or recombinant 
IL-22 (30 ng/mL) (Peprotech) or day 5 culture supernatants 
from FACS sorted anti-CD3/anti-CD28 with or without IL-21 
activated naïve (CD3+ CD4+ CD45RA+CD27+) T  cells and 
cultured for 12 h with Golgi-Stop™. For blocking experiments, 
antihuman IFNγ antibody (10  µg/mL) or antihuman/mouse 
IL-22 antibody (10 ng/mL) or their respective isotype controls 
(10 ng/mL) were used. Adherent HaCaT cells harvested with 
0.25% trypsin- dthylenediaminetetraacetic acid (Gibco) and 
intracellular CXCL-9 production measured by flow cytometry 
as described above.
Phosphoflow sTaT1
HaCaT cells were stimulated with recombinant IL-22 (50 ng/mL) 
and/or recombinant IFNγ (0.5 ng/mL) for 15  min. Cells were 
washed and fixed with 2% paraformaldehyde, then washed with 
cold 1× phosphate-buffered saline before resuspending in ice 
cold methanol at 4°C for 30 min. Cells were washed in magnetic-
activated cell sorting buffer and stained intracellularly with 
anti-STAT1 antibody or anti-STAT1 isotype for 60 min at room 
temperature. The expression of pSTAT1 in HaCaT cells was then 
measured immediately by flow cytometry.
statistical analysis
Statistical analysis was performed using GraphPad Prism ver-
sion 5 (GraphPad Software, San Diego, CA, USA). Data were 
assessed for normality using the Kolmogorov–Smirnof test. 
Where data were normally distributed paired or unpaired 
student t-test was used unless three independent comparisons 
applied when one-way analysis of variance (ANOVA) with 
Tukey’s post hoc analysis was used. Where data were not normally 
distributed, the non-parametric Kruskal–Wallis (with Dunn’s 
post-test analysis) was used. A p-value of <0.05 was considered 
significant.
resUlTs
The Frequency of cD4+ il-22+ cells 
reduced in the Peripheral blood of  
Psa Patients compared with healthy 
individuals
The production of IL-22 and IFNγ was quantitated in activated 
CD4+ T cells from patients with PsA. The frequency of CD4+IL-22+ 
T cells was less in PsA compared with healthy controls irrespec-
tive of therapy including with the TNF inhibitor adalimumab 
(Figure 1A). The percentage of Th22 cells (IL-22+IL-17− CD4+ 
T cells) was also reduced (Figure 1B). In contrast, the percent-
age of CD4+IFNγ+ T cells was similar between PsA patients and 
healthy controls (Figure  1C) resulting in an increased ratio of 
IFNγ:IL-22 in CD4+ T cells in PsA compared with healthy con-
trols (Figure 1D).
T helper-22 cells express the chemokine receptors CCR6, 
CCR4, and CCR10. CCR6 expression was globally reduced on 
CD4+ T  cells of PsA patients compared with healthy controls 
(Figure 2A). The majority of IL-22+ IL-17− CD4+ T cells in the 
healthy control samples expressed CCR6, but this was significantly 
less in PsA patients (Figure 2B). CCR4, CCR10, and CXCR3 were 
expressed at much lower frequencies on IL-22+ CD4+ T  cells 
(~10–20%) without any differences between patients and controls 
(Figure 2B). In contrast to the reduction in CCR6 expression on 
IL-22+ CD4+ T cells, there was no change in CXCR3 expression 
on T helper-1 (Th1) cells (Figure 2C).
iFnγ and il-22 Production increased  
in activated “naïve” Psa T cells
Next we investigated which T-cell subset contributed to IL-22 
dysregulation. T-cell subsets were classified as naïve (CD3+CD
FigUre 1 | Frequency of IL-22+ CD4+ T cells reduced in PsA compared with healthy controls. PBMCs were stimulated with anti-CD3/anti-CD28 and the production  
of IL-22 and IFNγ quantified using flow cytometry. Representative flow cytometry and cumulative data showing frequency of (a) CD4+IL-22+ T cells and (b) IL-22+IL-17− 
CD4+ T cells in healthy controls (healthy) (n = 18), untreated/DMARD PsA patients (untreated/DMARD PsA) (n = 20), and adalimumab treated patients (n = 9).  
(c) Representative flow cytometry and cumulative data showing frequency of IFNγ+CD4+ T cells in healthy (n = 10), Untreated/DMARD PsA (n = 20) and adalimumab 
treated patients (n = 8). *p < 0.05; **p < 0.01 one-way ANOVA with Tukey’s post hoc analysis. Error bars represent mean ± SE. (D) Bar graph showing cumulative total 
IFNγ/IL-22 ratio in CD4+ T-cell Kruskal–Wallis test with Dunn’s post hoc analysis *p < 0.05; **p < 0.01. Error bars represent mean ± SE. ANOVA, analysis of variance; 
DMARD, disease-modifying antirheumatic drug; IFNγ, interferon-gamma; IL-22, interleukin-22; PBMCs, peripheral blood mononuclear cells; PsA, psoriatic arthritis.
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FigUre 2 | Frequency of CD4+CCR6+IL-22+ T cells in PsA reduced as compared with healthy controls. (a) Representative FACS plot and cumulative scatter  
plot showing percentage CCR6+CD4+ T cells in healthy (n = 27) and untreated/DMARD PsA (n = 53). (b) Cumulative dot plot showing CCR6, CXCR3, CCR4,  
and CCR10 expression on IL-22+IL17−IFNγ− CD4+ T cells; healthy (n = 20) and untreated/DMARD PsA (n = 18). (c) Cumulative dot plot showing CCR6, CXCR3,  
and CCR4 expression on IFNγ+IL-22−IL-17− CD4+ T cells; healthy (n = 15) and untreated/DMARD PsA (n = 20). **p < 0.01 unpaired Student’s t-test. Error bars 
represent mean ± SE. DMARD, disease-modifying antirheumatic drug; FACS, fluorescence-activated cell sorting; IFNγ, interferon-gamma; IL-22, interleukin-22; 
PsA, psoriatic arthritis.
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4+CD27+CD45RA+), central memory (CD3+CD4+CD27+CD4
5RA−), and effector memory (CD3+CD4+CD27-CD45RA−) 
cells based on the presence or absence of the surface mol-
ecules CD45RA and CD27 (21). The percentage of IL-22+ 
CD4+ T cells was reduced in activated central memory CD4+ 
T  cells of PsA patients without any significant difference in 
IFNγ expression or in the ratio of IL-22:IFNγ (Figure S1 in 
Supplementary Material). The production of both these 
cytokines was undisturbed from activated effector CD4 
memory cells (Figures S1A,B in Supplementary Material). 
Unexpectedly, the frequency of IL-22+ and IFNγ+ naïve CD4+ 
T  cells were significantly elevated in PsA patients compared 
with healthy controls (Figures 3A,B). Quantification of IL-22 
and IFNγ levels in day 3 culture supernatants revealed mark-
edly increased secretion of both these cytokines from naïve 
T cells, which was lessened in patients treated with adalimumab 
(Figure 3C). The IFNγ:IL-22 ratio from these unconventional 
naïve T cells more than doubled in PsA patients compared with 
healthy controls with amelioration of these changes following 
anti-TNF therapy (Figure 3D). There was no significant cor-
relation between the skin or joint disease activity scores and 
the percentage of naïve T  cells or the ratio of IFNγ:IL-22 
production from these unconventional naïve T  cells in PsA 
(data not shown).
activated naïve cD4+ T cells showing 
Features of Memory cells and Promoting 
cXcl-9 Production from hacaT 
Keratinocytes
Studies have shown that a population of long-lived memory 
T cells with characteristics of naïve T cells exists with self-renewal 
properties and the ability to repopulate the central memory, 
effector memory, and effector T-cell pools (22, 23). Prompted by 
the aberrant cytokine producing properties of ostensibly naïve 
CD4 T  cells from PsA patients, we further characterized this 
population with respect to CCR7, CD62L, CXCR3, CCR6, CD95 
(Fas), and IL-2 receptor beta (IL-2Rβ) expression. Greater than 
FigUre 3 | Activated naïve CD4+ T cells from PsA patients producing more IL-22 and IFNγ compared with healthy controls. Purified naïve 
(CD3+CD4+CD45RA+CD27+) T cells were stimulated with anti-CD3/anti-CD28. After 5-day culture, cells were restimulated with PMA/ionomycin and  
intracellular IL-22 and IFNγ production evaluated. Supernatants were taken at day 3 for quantitative ELISA. (a) Representative flow cytometry plot and  
(b) cumulative data showing frequency of IL-22+ and IFNγ+ CD4+ T cells, healthy (n = 10), untreated/DMARD PsA (n = 16), and adalimumab-treated PsA (n = 5) 
patients. (c) Concentration of IL-22 and IFNγ in day 3 naïve T-cell supernatants: healthy (n = 8), untreated/DMARD PsA patients (n = 10), and adalimumab-
treated PsA patients (n = 5). (D) Bar graph showing cumulative IFNγ/IL-22 ratio in the purified naïve T cells based on flow cytometry staining: healthy (n = 10), 
untreated/DMARD PsA (n = 16), and adalimumab-treated PsA patients (n = 5) *p < 0.05; **p < 0.01; ***p < 0.001; Kruskal–Wallis test with Dunn’s post hoc 
analysis (error bars represent mean ± SE). DMARD, disease-modifying antirheumatic drug; IFNγ, interferon-gamma; IL-22, interleukin-22; PMA, phorbol 
myristate acetate; PsA, psoriatic arthritis.
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95% of CD27+CD45RA+CD4+ T cells in healthy controls and PsA 
patients expressed the naïve T-cell marker CCR7 (Figure 4A). 
However, the percentage of CD27+CD45RA+CD4+ T  cells 
expressing the lymph node homing lectin CD62L was reduced 
in PsA patients compared with healthy controls with a similar 
trend in anti-TNF-treated patients (Figure  4A). Furthermore, 
there was a significant increase in CXCR3 expression in naïve 
T  cells from PsA patients compared with healthy controls 
(Figure 4A). The expression of both CD95 and IL-2Rβ were low 
in the CD27+CD45RA+CD4+ T-cell population.
We next evaluated the proliferative capacity of these uncon-
ventional CD27+CD45RA+CD4+ naïve T  cells. Ex vivo Ki67 
expression was similar between healthy controls, PsA patients, 
and adalimumab-treated PsA patients (Figures 4B,C). However, 
upon stimulation the unconventional naïve T  cells from PsA 
patients had a far greater proliferative capacity compared with 
naïve T cells from healthy controls which was fully reversed in 
anti-TNF-treated patients (Figures 4B,C).
An in vitro model of inflammation was utilized to assess the 
impact of IL-22 and IFNγ dysregulation in the CD27+CD45RA 
CD4+ unconventional naïve T-cell subset. Culture supernatants 
from the unconventional naïve T cells isolated from PsA patients 
promoted higher expression of the Th1 chemokine CXCL-9 by 
HaCaT  cells (a keratinocyte cell line) after short-term culture 
compared with healthy controls and patients treated with anti-
TNF therapy (Figures 4D,E). CXCL-9 production stimulated by 
the unconventional naïve T-cell supernatants was inhibited by an 
IFNγ-blocking antibody (Figures 4F,G).
FigUre 4 | Continued
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il-22 regulating iFnγ-Mediated cXcl9 
release from hacaT cells stimulated by 
naïve cD4+ T cells from Psa Patients
To investigate whether there was a relationship between IFNγ 
and IL-22, we initially cultured HaCaT cells with recombinant 
IL-22 (rIL-22) and/or IFNγ (rIFNγ). IL-22 suppressed IFNγ-
driven STAT1 phosphorylation (Figure  5A) and the ability of 
rIFNγ to induce CXCL-9 (Figures 5B,C).
The cytokine IL-21 can trigger IL-22 production in CD4+ 
T  cells (24). We thus investigated whether IL-21 promoted 
IL-22 production in activated unconventional naïve PsA CD4+ 
FigUre 5 | IL-22 suppressing IFNγ-driven pSTAT1 and CXCL-9 production in HaCaT keratinocytes. HaCaT keratinocytes were cultured for 15 min with different 
concentrations of recombinant IL-22 but with a fixed concentration of IFNγ (0.5 ng/mL). pSTAT1 expression was detected by flow cytometry. Alternatively, 
HaCaT cells were stained for intracellular CXCL-9 expression. (a) Representative histogram showing pSTAT1 expression in HaCaT cells (representative of four 
independent experiments). (b,c) Representative histogram showing MFI for CXCL9 expression and bar graph depicting cumulative fold change in CXCL9 
expression in HaCaT cells after stimulation with IL-22 (30 ng/mL) and/or IFNγ (1 ng/mL) (n = 5). *p < 0.05 unpaired Student’s t-test. Error bars represent 
mean ± SE. IFNγ, interferon-gamma; IL-22, interleukin-22; MFI, median fluorescent intensity.
FigUre 4 | Continued  
The unconventional naïve CD4+ T cells from PsA patients exhibiting some phenotypic and functional features of memory cells and promoting CXCL9 expression  
from HaCaT keratinocytes. PBMCs were surface stained for CCR7, CD62L, CXCR3, CD95, and IL-2Rβ and percentage expression on naïve 
(CD3+CD4+CD45RA+CD27+) T cells evaluated. (a) Frequency of CCR7+, CD62L+, CXCR3+, CD95+, and IL-2Rβ+ cells in healthy (n = 11–16): untreated/DMARD PsA 
(n = 19–32) and adalimumab-treated PsA (n = 6–8) patients. *p < 0.05 Kruskal–Wallis test with Dunn’s post hoc analysis. Error bars represent mean ± SE.  
(b,c) Naïve (CD3+CD4+CD45RA+CD27+) T cells were purified and Ki67 expression measured at baseline and after 5-day stimulation with anti-CD3/anti-CD28. 
Representative flow cytometry plot and cumulative graph showing frequency of CD4+Ki67+ T cells at baseline and after stimulation in healthy (n = 6), untreated/
DMARD PsA (n = 9) and adalimumab-treated PsA (n = 4) patients. *p < 0.05; **p < 0.01 unpaired Student’s t-test. HaCaT cells were stimulated with day 5 activated 
T-cell supernatants with or without anti-IFNγ from healthy, untreated/DMARD PsA, and adalimumab-treated PsA patients. (D) Representative histogram depicting 
MFI of CXCL-9 expression in HaCaT cells. (e) Bar graph showing CXCL-9 MFI expression in stimulated HaCaT cells, healthy (n = 6), untreated/DMARD PsA 
patients (n = 11), and adalimumab-treated PsA patients (n = 4) *p < 0.05 unpaired Student’s t-test. Error bars represent mean ± SE. (F,g) Representative histogram 
and cumulative data showing MFI CXCL-9 expression in HaCaT cells stimulated with supernatant with or without anti-IFNγ from untreated/DMARD PsA activated 
naïve CD4+ T cells (n = 5) *p < 0.05 paired Student’s t-test. DMARD, disease-modifying antirheumatic drug; IFNγ, interferon-gamma; IL-22, interleukin-22; MFI, 
median fluorescent intensity; PBMCs, peripheral blood mononuclear cells; PsA, psoriatic arthritis.
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T cells and what functional effects increasing IL-22 availability 
would have on CXCL9 production. After 5-day culture, IL-21 
increased IL-22 production by naïve CD4+ T  cells from both 
healthy controls and PsA patients (Figures  6A,B). However, 
IL-21-driven expansion of IFNγ+ T cells only occurred in healthy 
individuals (Figures  6A,B). We then assessed the functional 
consequences of increased IL-22 production. Inhibition of IL-22 
increased CXCL-9 expression driven by supernatants from the 
unconventional naïve CD4 T  cells isolated from patients with 
PsA but not from healthy controls or patients treated with adali-
mumab (Figures 6C,D).
DiscUssiOn
We found that the frequency of IL-22 producing CD4 T  cells 
following activation in vitro is reduced in PsA patients compared 
FigUre 6 | Blockade of IL-22 in supernatants from the unconventional naïve T cells from PsA patients further elevates IFNγ driven CXCL-9 production in HaCaT 
keratinocytes. Purified naïve T cells were activated with anti-CD3/anti-CD28 with or without recombinant IL-21 (30 ng/mL) for 5 days before assaying intracellular 
cytokine production. (a) Representative flow cytometry depicting the frequency of IL-22+ and IFNγ+ CD4 T cells in PsA and healthy. (b) Cumulative paired 
expression of IL-22 and IFNγ in anti-CD3/anti-CD28 and anti-CD3/anti-CD28+ IL-21 stimulated cells; healthy (n = 6), untreated/DMARD PsA (n = 10) IFNγ: healthy 
(n = 8), untreated/DMARD PsA (n = 11). *p < 0.05; **p < 0.01; ***p < 0.001 paired Student’s t-test. HaCaT cells were stimulated with day 5 supernatants from 
anti-CD3/CD28/IL-21 activated naïve CD4+ T cells with or without anti-IFNγ or anti-IL-22 for 12 h in the presence of Golgi Stop and intracellular CXCL-9 production 
evaluated. (c) Representative histogram showing mean fluorescent intensity of CXCL-9 expression in HaCaT cell stimulated with supernatant from Unt PsA naïve 
CD4+ T cells with or without anti-IFNγ or anti-IL-22. (D) Plot showing cumulative MFI CXCL9 in presence or absence of anti-IL-22; healthy (n = 6) untreated/DMARD 
PsA (n = 6), adalimumab (n = 4); **p < 0.01 paired Student’s t-test. DMARD, disease-modifying antirheumatic drug; IFNγ, interferon-gamma; IL-22, interleukin-22; 
MFI, median fluorescent intensity; PsA, psoriatic arthritis.
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with healthy controls, whereas the percentage of CD4+IFNγ+ 
remained stable. This reduction of IL-22 expressing CD4+ T cells 
is principally accounted for by changes in the central memory 
CD4+ T-cell compartment. Comparative data on IL-22 expres-
sion in peripheral CD4+ T cells from PsA and healthy controls 
are limited with conflicting results from peripheral blood and 
synovial fluid (6, 25, 26). The reduced frequency of CCR6+ 
IL-22+ CD4+ cells in the peripheral blood of PsA patients could 
be explained by their migration to sites of inflammation possibly 
through a CCR6-dependent mechanism. About two-thirds of 
our patients also had psoriasis, though mostly minimal disease 
(Table 1), and therefore we cannot distinguish the immune con-
sequences of inflammatory joint from inflammatory skin disease, 
nor determine to which inflammatory site the IL-22+ cells would 
be directed toward.
The most surprising finding with respect to IL-22 production 
by CD4+ T cells in patients with PsA occurred within the “naïve” 
T-cell compartment. Significant polarization in this unconven-
tional naïve subset was associated with a twofold increase in the 
ratio of IFNγ+:IL-22+ production, which was greater than in the 
other CD4+ T-cell subsets underscoring the pro-inflammatory 
potential of naïve CD4 T cells in PsA. Alterations in the pheno-
type of these unconventional naïve CD4 T cells in PsA suggest 
adoption of memory properties similar to that observed following 
infection (23) but are also present in healthy individuals at low 
frequencies (27). Moreover, these T cells with a naïve phenotype 
produce effector cytokines and respond rapidly to stimulation 
and primed to differentiate into effector and memory cells, 
thereby contributing to disease exacerbations. Like conventional 
naïve CD4+ T cells, these memory cells with a naïve phenotype 
can circulate between the blood and lymphoid tissue but their 
lower expression of CD62L together with increased expression of 
CXCR3 would enhance migration to sites of inflammation (28). 
Although the unconventional naïve T  cells described here did 
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not express CD95 or IL-2Rβ which would suggest that they are 
distinct from antigen-experienced cells with memory stem cell-
like properties, the high proliferative response and somewhat 
increased CXCR3 expression are characteristic of this T-cell 
population (22, 29). Alternatively, these PsA unconventional 
naïve T cells could be closer to the more recently described naïve 
T  cells with a memory cell phenotype which do not express 
CD95 (23). The majority of the abnormalities observed with this 
unconventional naïve CD4 subset such as the enhanced prolif-
erative capacity and ability to increase CXCL-9 production were 
reversed by anti-TNF therapy, suggesting that a TNF-dependent 
mechanism contributes to these changes in PsA. In contrast, anti-
TNF did not reverse the lower percentage of total and central 
memory IL-22 expressing CD4 T cells in patients with PsA. Thus, 
it appears that anti-TNF principally targets the aberrant cytokine 
production and proliferative response of the dysregulated naïve 
CD4 T cells in PsA rather than other CD4 T-cell subsets.
It has previously been shown that the Th-17 cytokine IL-21 
stimulates IL-22 release in CD4+ T  cells (24). We confirmed 
that IL-21 promoted IL-22 production in activated naive CD4+ 
T cells of PsA patients and healthy controls. In healthy individu-
als, but not patients with PsA, IL-21 also induced increased IFNγ 
expression. There is controversy as to whether IL-21 modulates 
CD4 T-cell IFNγ production; we speculate that increased IL-21, 
which occurs in PsA, dampens the IFNγ but not the IL-22 
response to IL-21, which was added in activated naïve T-cell 
cultures (24, 30). Naïve T-cell-derived culture supernatants, 
activated in the presence of IL-21 to enhance IL-22 production, 
induced CXCL-9 production from HaCaT cells. IL-22 blockade 
further enhanced CXCL9 production from HaCaT cells. These 
data highlight a potential regulatory role for IL-22 in PsA, in 
particular inhibition of the production of CXCL9 which has 
been implicated in the pathogenesis of PsA (31). Our findings 
are consistent with the suppression of CXCL-9 by IL-22 in an 
animal model of lung fibrosis which limited recruitment of 
CD4+CXCR3+ T cells and attenuation of lung inflammation and 
fibrosis (32). More recently, anti-TNF therapy has been shown 
to be effective in inflammatory bowel disease in part through 
suppressing IL-22-binding protein thereby implicating IL-22 
as a protective cytokine (20). Thus, IL-22 is emerging as a key 
regulatory cytokine in a number of different diseases. However, 
contrasting these reports IL-22 has frequently been identified 
as pro-inflammatory in a range of diseases including psoriasis, 
though little is understood about its role in PsA. For instance, 
low levels of IL-22 binding protein and high IL-22 concentra-
tions are associated with worse inflammation in psoriasis (33). 
Moreover, IL-22 induces psoriasis like skin changes and its 
blockade can be as effective as anti-TNF in a psoriasis model 
(34). The fact that efforts to target IL-22 in patients with psoriasis 
have largely stalled perhaps attests to the challenges in targeting 
this cytokine which has potentially opposing roles often in the 
same disease.
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FigUre s1 | (a) IL-22 and IFNγ production from purified central memory 
(CD3+CD4+CD45RA−CD27+) T cells healthy (n = 13), untreated/DMARD PsA 
n = 17, adalimumab-treated PsA (n = 5) and effector memory (CD3+ 
CD4+CD45RA−CD27−) T cells, healthy (n = 9), untreated/DMARD PsA (n = 12), 
adalimumab-treated PsA (n = 4) after 5-day stimulation with anti-CD3/anti-CD28. 
(B) IFNγ:IL-22 ratio in central memory cells and effector memory T cells.
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